Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00551070 · OUTCOME

Adverse Events (Grade 3 or Higher) During First Cycle of Treatment

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
Cycle 1

Analysis population: Eligible and treated patients.

Groups in this outcome

AZD6244

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD624452

Reported measurements

Leukopenia
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Thrombocytopenia
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Neutropenia
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Anemia
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62442Not reported010Not reported
Allergy/Immunology
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Auditory/Ear
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Cardiac
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62442Not reported010Not reported
Coagulation
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Constitutional
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62444Not reported013Not reported
Dermatologic
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD624412Not reported423Not reported
Gastrointestinal
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD624413Not reported626Not reported
Genitourinary/Renal
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62442Not reported010Not reported
Hemorrhage
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Infection
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Lymphatics
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Metabolic
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Musculoskeletal
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Neurosensory
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Other Neurological
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Ocular/Visual
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62440Not reported07Not reported
Pain
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62444Not reported013Not reported
Pulmonary
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD62444Not reported013Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Leukopenia
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Thrombocytopenia
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Neutropenia
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        10
        value
        2
    title
    Anemia
  5. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Allergy/Immunology
  6. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Auditory/Ear
  7. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        10
        value
        2
    title
    Cardiac
  8. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        7
        value
        0
    title
    Coagulation
  9. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        13
        value
        4
    title
    Constitutional
  10. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4
        upper Limit
        23
        value
        12
    title
    Dermatologic
  11. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6
        upper Limit
        26
        value
        13
    title
    Gastrointestinal
  12. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        10
        value
        2
    title
    Genitourinary/Renal
denoms
  1. counts
    1. group Id
      OG000
      value
      52
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)
    id
    OG000
    title
    AZD6244
param Type
NUMBER
population Description
Eligible and treated patients.
reporting Status
POSTED
time Frame
Cycle 1
title
Adverse Events (Grade 3 or Higher) During First Cycle of Treatment
type
PRIMARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice